Lilly’s tirzepatide sheds lean muscle harder than Novo’s semaglutide, study suggests
While Eli Lilly’s tirzepatide helps patients drop more weight than Novo Nordisk’s semaglutide, this might come with greater loss in lean body mass, according to a new study awaiting peer review. The analysis, shared as ...
By Endpoints News
· Apr 17, 2026
· via Endpoints News
Image: Endpoints News
Tags
theweekformat:headlineheadlineEndpoints News
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekSTAT News ↗
“These sides aren't talking to each other. And there's a lot riding on it”: The hosts of “Why Should I Trust Y…
The WeekBriefing
KFF’s new weekly podcast debuts April 2026, diving into healthcare’s financial and policy mechanics, starting …
The WeekBriefing
Drug Channels’ April roundup highlights how vertical integration and copay maximizers are changing the economi…